Therapeutics News and Research

RSS

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Kolltan Pharmaceuticals, Inc., a next-generation oncology therapeutics company, announced today that it has raised $10 million in investments and related payments from an affiliate of Celtic Therapeutics Holdings L.P. (“Celtic Therapeutics”) and Tichenor Ventures, LLC.

20 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

InVivo Therapeutics sponsors fundraising event to support patients with spinal cord injuries

InVivo Therapeutics will be the lead champion level sponsor for the black tie gala fundraiser to support the Greater Boston Chapter of the National Spinal Cord Injury Association, a non-profit organization that offers programs and services to those with spinal cord injury/disease (SCI).

20 Jan 2010

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia’s RNA Silencing: Mechanism, Biology and Application held January 14-19 in Keystone, Colorado.

20 Jan 2010

Researchers show how gliomas can evade drugs aimed at blocking EGFR

Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, can evade drugs aimed at blocking a key cell signaling protein, epidermal growth factor receptor (EGFR),that is crucial for tumor growth.

20 Jan 2010

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

20 Jan 2010

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.

20 Jan 2010

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that U.S. gastroenterologists will treat a larger proportion of treatment nonresponder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe's telaprevir than Merck's boceprevir.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Liquidia Technologies completes $20M Series C financing round

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, today announced it has completed a $20 million round of Series C financing. Canaan Partners led the Series C round, which also included Pappas Ventures and Morningside Venture Investments Limited as new investors. Previous investors, including New Enterprise Associates and Firelake Capital, also participated in the financing round.

20 Jan 2010

Perseid Therapeutics to co-develop and commercialize next-generation CTLA4-Ig therapeutics

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.

19 Jan 2010

Psoriasis therapy costs outpace inflation

Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals.

19 Jan 2010

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Alcon, the world’s leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

18 Jan 2010

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

Dramatically enhanced image contrast could revolutionize diagnostics and therapeutics

A Northwestern University study shows that coupling a magnetic resonance imaging (MRI) contrast agent to a nanodiamond results in dramatically enhanced signal intensity and thus vivid image contrast.

18 Jan 2010

HHMI: Distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors

According to modern biology textbooks, a single genetic mutation is rarely enough to cause cancer. It is generally thought that cells must accumulate a series of mutations that work together to trigger tumor development.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

ERA-NET PathoGenoMics announces third international joint call for infectious disease research

ERA-NET PathoGenoMics, an initiative of the European Commission aimed at advancing transnational genome-based research programs on human-pathogenic microorganisms, announced today the third international joint call. The third joint call allocated €8.5 Million over 3 years to relevant research projects which will be provided by ERA-NET PathoGenoMics partner organizations from Austria, France, Germany, Hungary, Israel, Portugal, Slovenia and Spain.

13 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

Therapeutics News and Research

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

InVivo Therapeutics sponsors fundraising event to support patients with spinal cord injuries

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

Researchers show how gliomas can evade drugs aimed at blocking EGFR

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Liquidia Technologies completes $20M Series C financing round

Perseid Therapeutics to co-develop and commercialize next-generation CTLA4-Ig therapeutics

Psoriasis therapy costs outpace inflation

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Sirnaomics certifies polypeptide nanoparticle technology

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Dramatically enhanced image contrast could revolutionize diagnostics and therapeutics

HHMI: Distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

ERA-NET PathoGenoMics announces third international joint call for infectious disease research

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News